- Home
- MAC vs AKRO Comparison
MAC vs AKRO Comparison
Compare MAC & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAC | AKRO |
|---|---|---|
| Founded | 1964 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.5B |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MAC | AKRO |
|---|---|---|
| Price | $18.70 | $54.65 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 11 |
| Target Price | $19.67 | ★ $73.56 |
| AVG Volume (30 Days) | 1.7M | ★ 2.4M |
| Earning Date | 11-04-2025 | 11-07-2025 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,099,978,000.00 | N/A |
| Revenue This Year | $12.31 | N/A |
| Revenue Next Year | $1.09 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.55 | N/A |
| 52 Week Low | $12.48 | $21.34 |
| 52 Week High | $21.80 | $58.40 |
Technical Indicators
Market Signals| Indicator | MAC | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 66.79 | 68.63 |
| Support Level | $17.00 | $54.30 |
| Resistance Level | $17.87 | $54.70 |
| Average True Range (ATR) | 0.48 | 0.17 |
| MACD | 0.18 | -0.10 |
| Stochastic Oscillator | 93.57 | 71.07 |
Price Performance
Historical ComparisonAbout MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 29 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with two power centers and seven other real estate assets. The company's total portfolio has 42.2 million square feet of gross leasable area and averaged $849 sales per square foot over the 12 months ended in June 2025.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.